Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients

被引：0
|
作者：
Fizazi, K. [1 ]
Bernard-Tessier, A. [1 ]
Barthelemy, P. [2 ]
Utriainen, T. [3 ]
Roubaud, G. [4 ]
Flechon, A. [5 ]
van der Voet, J. C. M. [6 ]
Mescam, G. Gravis [7 ]
Ratta, R. [8 ]
Jones, R. H. [9 ]
Parikh, O. A. [10 ]
Tanner, M. M. E. [11 ]
Garratt, C. [12 ]
Nevalaita, L. [13 ]
Pohjanjousi, P. [13 ]
Ikonen, T. [13 ]
Antonarakis, E. S. [14 ]
Cook, N. [15 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] ICANS Inst Cancerol, Med Oncol, Strasbourg, France
[3] Univ Helsinki, Oncol, Cent Hosp, Helsinki, Finland
[4] Inst Bergonie, Med Oncol, Bordeaux, France
[5] Ctr Leon Berard, Med Oncol, Lyon, France
[6] James Cook Univ Hosp, Radiotherapy, Middlesbrough, Cleveland, England
[7] IPC Inst Paoli Calmettes, Med Oncol, Marseille, France
[8] Hop Foch, Med Oncol, Suresnes, France
[9] NHS Wales, Velindre Canc Ctr, Cardiff, Wales
[10] Lancashire Teaching Hosp NHS Fdn Trust, Royal Preston Hosp, Oncol, Preston, Lancs, England
[11] Tampere Univ Hosp Tays, R&D, Tampere, Finland
[12] Orion Corp Orion Pharma, R&D, Newbury NG1 1AH, Berks, England
[13] Orion Corp Orion Pharma, R&D, Espoo, Finland
[14] Johns Hopkins Univ, Med Oncol, Baltimore, MD USA
[15] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364MO
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [31] Borxpten: A phase II study of bortezomib (B) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with PTEN deletion.
    Thomas, Vinay Mathew
    Moynier, Colin
    Boucher, Kenneth M.
    Nordblad, Blake
    Clement, Susan
    Esplin, Michelle
    Kohli, Manish
    Gupta, Sumati
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS258 - TPS258
  • [32] BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
    De Souza, Andre
    Aggarwal, Rahul
    Safran, Howard
    Golijanin, Dragan
    Wood, Roxanne
    Olszewski, Adam
    El-Deiry, Wafik S.
    Mega, Anthony
    Carneiro, Benedito A.
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study
    Gardner, Thomas A.
    Petrylak, Daniel Peter
    Corman, John M.
    Hall, Simon
    Weinstein, Ralph
    Keyser, Robert
    Sims, Robert Brownell
    Sanders, Amanda
    Sheikh, Nadeem A.
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [34] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
    Gopalakrishnan, Dharmesh
    Kirk, Jason
    Davis, John
    George, Saby
    Levine, Ellis Glenn
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tang, Dean
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [36] Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC)
    Cetnar, J. P.
    Rosen, M. A.
    Vaughn, D. J.
    Haas, N. B.
    Troxel, A. B.
    Song, H.
    Adluru, G.
    Flaherty, K. T.
    O'Dwyer, P. J.
    Amaravadi, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Brown, Myles
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Jensen, A.
    Karunaratna, N.
    Wong, S.
    Shapiro, J.
    Weickhardt, A.
    Spain, L.
    Azad, A. A.
    Kwan, E.
    Muthusamy, A.
    Torres, J.
    Parente, P.
    Francis, P.
    Parnis, F. X.
    Goh, J.
    Gibbs, P.
    Tran, B.
    Anton, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1329 - S1330
  • [40] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345